Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dexmethylphenidate · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| dexmethylphenidate(d-mph) | DRUG | - |
* Diagnosis of cancer, excluding primary or metastatic brain tumors. * Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry. * Physical/neurological examination consistent with the absence o...
Dexmethylphenidate is a small molecule being studied for the treatment of fatigue in oncology patients. It is currently in Phase 2 clinical development for this indication, specifically for fatigue related to chemotherapy in adult cancer patients.
Dexmethylphenidate is a small molecule that is being investigated for its effects on fatigue and neurobehavioral function in cancer patients undergoing chemotherapy. The specific molecular target has not been disclosed in the available information.
Dexmethylphenidate is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY.
Dexmethylphenidate is in Phase 2 clinical development for the treatment of fatigue in oncology patients. It is an investigational drug and has not been approved by regulatory authorities for this use.
Dexmethylphenidate has been studied in one completed Phase 2 clinical trial, NCT00047476, which evaluated its use in treating fatigue and neurobehavioral function related to chemotherapy in adult cancer patients. The trial enrolled 160 participants in the United States.
Dexmethylphenidate is a distinct drug from methylphenidate, though both are related compounds. The available information does not indicate that dexmethylphenidate is also known by any other names.